Haermonics is a clinical stage medtech company that prevents blood-related complications post open-heart surgery. Their pioneering product – the Haermonics Pure^TM – is a highly effective flushing therapy that demonstratively prevents excessive blood-loss and the need for costly re-operations following open-heart surgery.

The Mibiton Solo funds is used to finance the production of several investigational devices used in (multicenter) clinical validation studies.